StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

Equities research analysts at StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a report issued on Wednesday. The brokerage set a “sell” rating on the medical technology company’s stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a report on Wednesday, October 2nd.

BIOLASE Stock Down 4.4 %

BIOLASE stock opened at $0.01 on Wednesday. The business has a 50 day moving average price of $0.01 and a two-hundred day moving average price of $0.04. The stock has a market cap of $287,300.20, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a 12 month low of $0.02 and a 12 month high of $1.94.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.